Publications en collaboration avec des chercheurs de Hospital Universitario 12 de Octubre (88)

2024

  1. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges

    Frontiers in Immunology, Vol. 15

  2. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  3. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  4. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  5. Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience

    Cancers, Vol. 16, Núm. 18

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

  2. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  3. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

    Life, Vol. 13, Núm. 9

  4. Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma (Journal of Hematology & Oncology, (2023), 16, 1, (76), 10.1186/s13045-023-01474-w)

    Journal of Hematology and Oncology

  5. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

    Frontiers in immunology

  6. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients (Frontiers in Immunology, (2023), 14, (1188818), 10.3389/fimmu.2023.1188818)

    Frontiers in Immunology

  7. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma

    Journal of Hematology and Oncology

  8. Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

    Frontiers in Pharmacology, Vol. 14

  9. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

    Leukemia, Vol. 37, Núm. 3, pp. 659-669

  10. Should we move to a genomic classification of neutrophilic myeloid neoplasms?

    Blood Advances

  11. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study

    Clinical Infection in Practice, Vol. 13

  3. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  4. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20